HBL20016

Last updated

HBL20016
Clinical data
Other namesHBL-20016
Drug class Serotonin receptor agonist; Serotonin 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT2C receptor agonist; Serotonergic psychedelic; Hallucinogen; Antiobsessional agent

HBL20016 is a non-selective serotonin receptor agonist and serotonergic psychedelic. [1]

It acts as an agonist of the serotonin 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT2C receptors. [1] Its activational potencies (EC50 Tooltip half-maximal effective concentration) are 645 nM for the serotonin 5-HT1A receptor, 1.64 nM for the serotonin 5-HT2A receptor, 3.42 nM for the serotonin 5-HT2B receptor, and 8.37 nM for the serotonin 5-HT2C receptor. [1] HBL20016 produces the head-twitch response (HTR), a behavioral proxy of psychedelic effects, in rodents, and hence would be expected to be hallucinogenic in humans. [1] It has shown antiobsessional-like effects in rodents, for instance against obsessive self-grooming. [1]

HBL20016 was first described in the scientific literature in December 2024. [1] It was developed by Negev Labs and Parow Entheobiosciences. [1] A related drug, HBL20017, which is a non-hallucinogenic agent with an otherwise mostly similar pharmacological profile, is under investigation for the potential treatment of obsessive–compulsive disorder. [1]

See also

References

  1. 1 2 3 4 5 6 7 8 Lerer B, Golding P, Brownstien M, Kozikowski A, Lifschytz T (December 2024). "ACNP 63rd Annual Meeting: Poster Abstracts P609-P914: P660. A Novel, Non-Hallucinogenic Psychedelic for the Treatment of Obsessive-Compulsive Disorder". Neuropsychopharmacology. 49 (Suppl 1): 418–594 (448–449). doi: 10.1038/s41386-024-02013-y . PMID   39643635.



This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.